Frömberg Anja, Rabe Michael, Aigner Achim
Rudolf-Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, University of Leipzig, Leipzig, Germany.
Int J Cancer. 2014 Dec 1;135(11):2537-46. doi: 10.1002/ijc.28895. Epub 2014 Apr 28.
SATB1 (special AT-rich binding protein 1) is a global chromatin organizer regulating the expression of a large number of genes. Overexpression has been found in various solid tumors and positively correlated with prognostic and clinicopathological properties. In colorectal cancer (CRC), SATB1 overexpression and its correlation with poor differentiation, invasive depth, TNM (tumor, nodes, metastases) stage and prognosis have been demonstrated. However, more detailed studies on the SATB1 functions in CRC are warranted. In this article, we comprehensively analyze the cellular and molecular role of SATB1 in CRC cell lines with different SATB1 expression levels by using RNAi-mediated knockdown. Using siRNAs with different knockdown efficacies, we demonstrate antiproliferative, cell cycle-inhibitory and proapoptotic effects of SATB1 knockdown in a SATB1 gene dose-dependent manner. Tumor growth inhibition is confirmed in vivo in a subcutaneous tumor xenograft mouse model using stable knockdown cells. The in-depth analysis of cellular effects reveals increased activities of caspases-3, -7, -8, -9 and other mediators of apoptotic pathways. Similarly, the analysis of E- and N-cadherin, slug, twist, β-catenin and MMP7 indicates SATB1 effects on epithelial-mesenchymal transition (EMT) and matrix breakdown. Our results also establish SATB1 effects on receptor tyrosine kinases and (proto-)oncogenes such as HER receptors and Pim-1. Taken together, this suggests a more complex molecular interplay between tumor-promoting and possible inhibitory effects in CRC by affecting multiple pathways and molecules involved in proliferation, cell cycle, EMT, invasion and cell survival.
SATB1(特殊富含AT序列结合蛋白1)是一种全局染色质组织者,可调节大量基因的表达。在各种实体瘤中均发现其过表达,且与预后及临床病理特征呈正相关。在结直肠癌(CRC)中,已证实SATB1过表达及其与低分化、浸润深度、TNM(肿瘤、淋巴结、转移)分期和预后的相关性。然而,有必要对SATB1在CRC中的功能进行更详细的研究。在本文中,我们通过RNAi介导的敲低,全面分析了SATB1在不同SATB1表达水平的CRC细胞系中的细胞和分子作用。使用具有不同敲低效率的小干扰RNA(siRNA),我们以SATB1基因剂量依赖性方式证明了SATB1敲低具有抗增殖、细胞周期抑制和促凋亡作用。在皮下肿瘤异种移植小鼠模型中,使用稳定敲低细胞在体内证实了肿瘤生长受到抑制。对细胞效应的深入分析显示,半胱天冬酶-3、-7、-8、-9及其他凋亡途径介质的活性增加。同样,对E-钙黏蛋白、N-钙黏蛋白、蛞蝓蛋白、扭曲蛋白、β-连环蛋白和基质金属蛋白酶7的分析表明,SATB1对上皮-间质转化(EMT)和基质破坏有影响。我们的结果还证实了SATB1对受体酪氨酸激酶和(原)癌基因(如HER受体和Pim-1)的影响。综上所述,这表明通过影响参与增殖、细胞周期、EMT、侵袭和细胞存活的多种途径和分子,在CRC中肿瘤促进作用与可能的抑制作用之间存在更复杂的分子相互作用。